# BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00411632** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Bexarotene
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00411632
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-29
- **Primary completion:** 2018-02-23
- **Final completion:** 2018-02-23
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411632, "BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00411632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*